추천 제품
Quality Level
분석
≥98% (HPLC)
양식
powder
광학 활성
[α]/D +80 to +95°, c = 1 (CHCl3)
색상
white to beige
solubility
DMSO: >5 mg/mL
저장 온도
−20°C
SMILES string
CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
InChI
1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
InChI key
GCKFUYQCUCGESZ-BPIQYHPVSA-N
유전자 정보
human ... PGR(5241)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
생화학적/생리학적 작용
Etonogestrel is a lipophilic molecule. Pharmacokinetics studies reveal that etonogestrel is bound to protein albumin in the blood. This remains independent of both endogenous and exogenous concentration of estradiol.
Etonogestrel is a third-generation progestin contraceptive. Etonogestrel is used as a contraceptive itself and is also the active metabolite of the drug desogestrel used in some combination contraceptives.
특징 및 장점
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
신호어
Danger
유해 및 위험 성명서
예방조치 성명서
Hazard Classifications
Carc. 2 - Repr. 1B
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
이미 열람한 고객
Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon
Contraception, 58(5), 283-288 (1998)
Clinical drug investigation, 32(6), 413-422 (2012-05-01)
The etonogestrel (ENG)-releasing implant is a subdermal progestogen-only contraceptive that provides coverage for up to 3 years. This long-acting hormonal contraceptive has been available in Europe since 1998 and in the US since 2006. To date, localization of non-palpable implants
American journal of obstetrics and gynecology, 206(6), 481-481 (2012-05-29)
The purpose of this study was to determine contraceptive continuation and repeat pregnancy rates in adolescents who are offered immediate postpartum etonogestrel implant (IPI) insertion. Participants in an adolescent prenatal-postnatal program were enrolled in a prospective observational study of IPI
Contraception, 83(3), 202-210 (2011-02-12)
The aim of this guidance is to review the management of unacceptable vaginal bleeding patterns in etonogestrel (ENG)-releasing contraceptive implant users concentrating, where possible, on the evidence for pharmacological treatments and identifying a pragmatic approach where this is not possible.
Headache, 52(8), 1246-1253 (2012-07-14)
To determine whether extended-cycle dosing of an ultralow dose vaginal ring contraceptive decreases frequency of migraine aura and prevents menstrual related migraine (MRM). Many women are denied therapy with combined hormonal contraceptives due to published guidelines that recommend against their
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.